Chengdu's HitGen Collaborates with Janssen on Oncology and Metabolics Discovery

HitGen, a Chengdu early-stage CRO, has formed a global multi-target collaboration with Janssen Biotech. The partnership will discover new small molecule candidates for oncology and metabolics targets, an operation facilitated by Johnson & Johnson Innovation. HitGen will search its DNA encoded libraries, which include more than 6 billion drug-like compounds, for drug leads. Financial details were not disclosed. More details.... Stock Symbol: (NYSE: JNJ) Share this with colleagues: // //